Last checked at 11 Feb 2021 07:00
Tissue Regenix Group plc
Move to Electronic Reporting
("Tissue Regenix" or the "Company")
Leeds, 11 February 2021 - Tissue Regenix Group (AIM:TRX) the regenerative medical devices company announces that it has written to all registered shareholders regarding its intention to adopt electronic communication methods for shareholder documents.
Tissue Regenix is seeking to adopt electronic communication in order to improve the Company's environmental sustainability efforts and ensure timely and cost-effective communications with all shareholders.
A letter has been posted to all registered shareholders from the Company's registrar, Link Group, and a copy of this letter will also be made available on the Company's website.
Shareholders wishing to continue to receive shareholder documents in printed form will need to notify Link Group no later than 10 March 2021 by completing and returning the response form within the letter, or through registering for a shareholder account on: www.signalshares.com
Those shareholders who do not return the response form will be deemed to have consented to receiving shareholder documents or information (including the annual report and notices of Company meetings) by means of the Tissue Regenix Group website: www.tissueregenix.com
A notice via email or mail, subject to the shareholder preference identified, will be sent to shareholders when new materials are available online including the annual report. Shareholders are entitled to change their preference of communication at any time in the future.
For more Information:
Tissue Regenix Group plc David Cocke Chief Financial Officer | www.tissueregenix.com Via Walbrook PR |
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price | Tel: +44 (0)207 710 7600
|
Walbrook PR Ltd Paul McManus / Alice Woodings / Lianne Cawthorne | Tel: +44 (0)20 7933 8780 TissueRegenix@walbrookpr.com
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.